Real-world effectiveness and safety of trifluridine-tipiracil (FTD/TPI) and bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC): The BeTAS trial.Ene 22, 2024 | Alberto Carral Maseda, ASCO, Borja Gonzalez Gómez, Comunicaciones a congresos
